The Prognostic Significance of Tumor Budding, Tumor Nodules, and Lymph Node Extracapsular Extension in Stage III Colorectal Cancer Patients

PURPOSE: The prognosis of advanced colorectal cancer patients may be different even for the same TNM staging. The characteristic features of tumors, such as tumor budding, tumor nodules, and extracapsular extension (ECE) of lymph nodes, can influence the disease progression and the outcome for patients. Tumor budding occurs what at the invasion front of colorectal adenocarcinomas, tumor cells, singly or in small aggregates, become detached from the neoplastic glands, and it can be divided it into two groups, low grade (0~16 foci in a field) and high grade (17 or more foci in a field). A tumor nodule is histologically identified within the fatty tissue or the detached fatty tissue around the dissected lymph nodes, or is a place picked up as lymph nodes from resected specimens which contain no lymph node components. ECE is defined as a tumor extension beyond the node capsule. The aims of this study were to evaluate the clinical significance of tumor budding, tumor nodules, and ECE of lymph nodes as prognostic factors in Stage III colorectal cancer patients. METHODS: We analyzed the disease-free and overall 5-year survival rates and recurrence rates in 94 Stage-III colorectal cancer patients according to tumor the budding intensity, the tumor nodules, and the lymph node ECE status. RESULTS: Of the entire group, the 5-year disease-free and overall survival rates were 49%, and 50%, respectively. The 5-year disease-free and overall survival rates were higher in the low-grade tumor budding group than in the high-grade group (58% vs 33%, P=0.045, 61% vs 39%, P=0.003). The 5-year disease-free and overall survival rates in patients with tumor nodules were lower than those in patients without one (44% vs 69%, P=0.086, 47% vs 77%, P=0.018). The recurrence rate was also higher in the group with tumor nodules than without one (80% vs 52%, P=0.045). The 5-year disease-free and overall survival rates were higher in the ECE negative group than in the positive one (68% vs 37%, P=0.018, 75% vs 42%, P=0.001). The recurrence rate was also higher in the ECE positive group than in the negative group (78% vs 46%, P=0.008). The existence of ECE and tumor nodule were strongly related to systemic recurrence (P=0.006, P=0.033), but not to the local recurrence (P=0.777, P=0.611). Considering the analysis of the recurrence pattern by N stage classification, there is no statistical difference in the N2 patient group, but there was in the existence of ECE and tumor nodule were strongly related to the systemic recurrence in N1 group (P=0.019, P=0.028). These three factors were scored according to the existence, and the score range was divided into two prognostic groups, high risk group (> or =2) and low risk group (<2). The high risk group was significantly associated with systemic recurrence (P= 0.004) rather than recurrence (P=0.865), and these score value were only significant in the N1 patient group (P=0.007) rather than in the N2 group (P=0.927). The high risk group also showed poor overall survival rate compared with the low risk one in only the N1 group (P=0.002), but nof in the N2 group (P=0.193). On multivariate analysis, UICC stage and ECE were two significant factors for tumor recurrence and the 5-year disease-free survival rate. CONCLUSIONS: These data showed that even if similar lymph node metastasis existed in advanced colorectal cancer patients, there was a different 5-year disease-free survival rate and overall survival rate according to the tumor budding, tumor nodule, and ECE status. On multivariate analysis, UICC stage and ECE were two significant factors for the tumor recurrence and the 5-year disease-free survival rate. Our results suggest that tumor budding, tumor nodule, and ECE of lymph node are excellent parameters to provide a confident prediction of clinical outcome.

A Clinical Analysis of PTEN Expressions in Breast Cancers / Journal of the Korean Cancer Association, 대한암학회지

PURPOSE: The PTEN gene, a novel tumor suppressor, is localized to chromosome 10q23.3 and shares extensive homology with the cytoskeletal protein, tensin. A high frequency of mutations at the PTEN locus has been described in a variety of neoplasms including breast cancer and Cowden Disease. However, the role of PTEN alterations and its association with clinicopathological factors have not been well established. We investigated the relationship between the PTEN expression and clinicopathological factors. MATERIALS AND METHODS: Formalin-fixed, paraffin-embedded tissues from 105 women with breast cancer were evaluated for the PTEN expression and were scored semi-quantitatively based on staining intensity and distribution. Results were statistically compared with clinicopathological factors. RESULTS: Forty-seven (45%) of the 105 breast cancers had a loss of the PTEN expression. In the recurrent group, 19 of 32 (59%) patients showed a loss of the PTEN expression, whereas in the non-recurrent group, only 28 of 73 (38%) patients showed a loss of the PTEN expression. The loss of PTEN expression correlated with estrogen receptors (ER) (p=0.027), recurrence (p=0.046), HER-2/neu overexpression (p=0.016), disease-free survival (p=0.0163), and overall survival (p=0.0357). In particular, when HER-2/ neu was overexpressed, the overall survival rate correlated with the loss of PTEN expression statistically (p=0.0454), whereas when HER-2/neu was negative, there was no correlation (p=0.9808). Progesterone receptor (PR) and disease stage had no relationship with the PTEN expression. CONCLUSION: Our results support that PTEN plays a role as a tumor suppressor in breast cancer and is a prognostic factor in predicting recurrence.

Clinical Analysis of Perforated Gastric Cancer

PURPOSE: Generalized peritonitis caused by a free perforation of gastric cancer is a rare condition, which occurs in 1~4% of all gastric cancer patients. To assess the characteristics of the patients and investigate the optimal treatment of choice, the data from 51 patients previous recent 10 years were retrospectively analyzed. METHODS: Between 1988 and 1997, 51 patients underwent surgical treatment for perforated gastric cancer. The clinicopathological features and survival rates of the resected group (n=39) and the non-resected group (n=12) were analyzed. RESULTS: The incidence was 0.78% and the mean age was 57 years. The most common tumor location was in the lower 1/3 in the resected group (n=21, 53.8%) and in the upper 1/3 in the non-resected group (n=6, 50%). Borrmann type 3, the poorly differentiated type, and a positive serosa invasion were more common in both groups. Liver and peritoneal metastases were observed in 2 cases (5.2%) and 7 cases (14.3%) in the resected group, and 4 cases (33.4%), and 3 cases (25%) in the non-resected group, respectively. Resectability found in 76.5%: 27 cases of a subtotal gastrectomy and 12 cases of a total gastrectomy. A limited lymph node dissection (D0, D1) was performed in 14 cases (35.9%) and an extended dissection (D2, D3) was performed in 25 cases (64.1%). The 5-year survival rate of stage I was 80%, 40% in stage II, 14% in stage III and 0% in stage IV, and the overall 5 year survival rate was 20.5% in the resected group and 0% in the non-resected group. The depth of invasion, lymph node metastasis and tumor stage significantly influenced the survival rate of the patients. CONCLUSION: Because a perforation of the gastric cancer may develop in every stage, surgeons must take care of these patients by the same way as with non-perforation cases.

Isolated Traumatic Gallbladder Perforation

Injuries to the gallbladder are found in about only 2% of patients with blunt abdominal trauma, and isolated gallbladder perforation is even less common. The gallbladder is less accessible to trauma because it is partially embedded in the liver, cushioned by the surrounding omentum and bowel, and shielded by the rib cage. It is usually associated with other visceral injuries, especially the liver. The leakage of bile from a ruptured gallbladder may not immediately produce symptoms of peritonitis, making an early diagnosis difficult, and causes delays to treatment. A 47-year-old man presented to our emergency department complaining of diffuse abdominal pain after a pedestrian traffic accident, but his vital signs were stable. In the laboratory tests, his hemoglobin was normal, but his blood chemistry showed mild jaundice (bilirubin 3.6 mg/dl). An abdominal computed tomogram showed pericholecystic and a right paracolic fluid collection, with a collapsed gallbladder. The patient underwent an operation under a diagnosis of hemoperitoneum, and when the peritoneal cavity was entered, the gallbladder was ruptured at the fundus, and about 500 cc of bile had accumulated in the abdominopelvic cavity. The other visceral organs were non-specific. We report a case of an isolated rupture of the gallbladder, with a review of the associated literature.

Acinar Cell Carcinoma of the Pancreas: A case report / 한국간담췌외과학회지

Acinar cell carcinoma of the pancreas is an uncommon neoplasm, comprises about 1% of pancreatic non-endocrine malignancies, arising from the pancreatic exocrine acinar cells rather than from ductal or neuroendocrine cells. Only ten cases of pancreatic acinar cell carcinoma has been reported in Korea. We reported a case of pancreatic acinar cell carcinoma in 50-year-old female with an one month history of rapid growing mass on epigastrium. Computed tomography shows a huge mass measured 12x11 cm, appeared cystic, in the body and tail of the pancreas. The patient underwent a distal pancreatectomy with splenectomy and total gastrectomy because of severe adhesion to the posterior gastric wall. After operation, the patient went rather rapidly downhill with progressive enlargement of peripancreatic lymph nodes, progression of pre-existing portal vein thrombosis and liver, bone metastasis inspite of adjuvant chemoradiotherpy and finally expired 17 months after operation.

Complete Remission after Chemotherapy in Stage IV Gastric Cancer

Complete remission (CR) following chemotherapy is defined as the disappearance of a previously known-malignancy, with no further development of a new tumor. The treatment of the stage IV gastric cancer, with a distant metastatic or locally advanced-unresectable condition is a surgical dilemma. Many therapeutic modalities including chemoradiation, immunotherapy or intraoperative thermal therapy, have been used for the management of this condition, but their results were still unsatisfactory. Although CR is infrequently reported, pathological confirmation by operation is quite rare. We experienced two cases of CR following FEP (5-FU 500 mg/m2, Epirubicin 50 mg/m2, and Cisplatin 60 mg/m2) chemotherapy; one was a case of locally advanced, unresectable gastric cancer with tumor extension through the adjacent structure, and extensive regional lymph nodes metastasis. We confirmed the pathological CR by a second look operation, a distal gastrectomy with D3 lymph node dissection. The patient is doing well, with no recurrence for 5 years. The other was a case of advanced gastric cancer, with hepatic metastasis, and was treated with the same chemotherapeutic regimens. However, he refused a second operation and recurrence of cancer was detected by a gastrofiberscopic biopsy, with metastatic nodule on liver at 8 and 14 months following CR, respectively. We suggest that although CR is achieved following chemotherapy, subsequent curative resection should be mandatory, as recurrence will develop after a few months.